{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:15:25Z","timestamp":1788225325454,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["5R01AI145645"],"award-info":[{"award-number":["5R01AI145645"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.isci.2026.116632","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:54:28Z","timestamp":1782820468000},"page":"116632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiviral activity of non-neutralizing antibodies during steady-state HIV-1 infection in humanized mice"],"prefix":"10.1016","volume":"29","author":[{"given":"Manoj S.","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maple","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoxing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-149X","authenticated-orcid":false,"given":"David D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116632_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.116632_bib2","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116632_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.116632_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2026.116632_bib5","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1097\/QAD.0000000000002011","article-title":"Antibody-dependent cellular cytotoxicity in HIV infection","volume":"32","author":"Forthal","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.isci.2026.116632_bib6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116632_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110368","article-title":"A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection","volume":"38","author":"Beaudoin-Bussi\u00e8res","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.116632_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01667-19","article-title":"Fc\u03b3 Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies","volume":"10","author":"Job","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.isci.2026.116632_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chom.2018.07.009","article-title":"A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus","volume":"24","author":"Gunn","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.isci.2026.116632_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116632_bib11","doi-asserted-by":"crossref","first-page":"10572","DOI":"10.1128\/JVI.05541-11","article-title":"A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fc\u03b3 receptors to define the role of effector functions in protection against HIV","volume":"85","author":"Moldt","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116632_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01743-21","article-title":"Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity","volume":"12","author":"Goldberg","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.isci.2026.116632_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010183","article-title":"Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice","volume":"18","author":"Hioe","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.116632_bib14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116632_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009101","article-title":"RV144 HIV-1 vaccination impacts post-infection antibody responses","volume":"16","author":"Mdluli","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.116632_bib16","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JVI.03230-13","article-title":"Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity","volume":"88","author":"Veillette","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116632_bib17","doi-asserted-by":"crossref","first-page":"12895","DOI":"10.1128\/JVI.02194-14","article-title":"Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection","volume":"88","author":"Acharya","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116632_bib18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1172\/JCI122466","article-title":"Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques","volume":"129","author":"Parsons","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.116632_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe3349","article-title":"Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates","volume":"13","author":"Hangartner","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.116632_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116632_bib21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.116632_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116632_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02322","article-title":"The Early Antibody-Dependent Cell-Mediated Cytotoxicity Response Is Associated With Lower Viral Set Point in Individuals With Primary HIV Infection","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116632_bib24","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.4049\/jimmunol.178.10.6596","article-title":"Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate","volume":"178","author":"Forthal","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.116632_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01025","article-title":"Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1","volume":"10","author":"Lewis","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116632_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005042","article-title":"Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques","volume":"11","author":"Santra","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.116632_bib27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cell.2017.06.048","article-title":"Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo","volume":"170","author":"Horwitz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116632_bib28","doi-asserted-by":"crossref","first-page":"18002","DOI":"10.1073\/pnas.2008190117","article-title":"Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo","volume":"117","author":"Wang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.116632_bib29","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.2008236117","article-title":"Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody","volume":"117","author":"Asokan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.116632_bib30","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1128\/JVI.00347-16","article-title":"Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies","volume":"90","author":"Von Bredow","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116632_bib31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41577-023-00858-w","article-title":"Antiviral neutralizing antibodies: from in vitro to in vivo activity","volume":"23","author":"Burton","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.116632_bib32","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/jvi.66.8.4784-4793.1992","article-title":"A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells","volume":"66","author":"Moore","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116632_bib33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116632_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/antib10020023","article-title":"Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography","volume":"10","author":"Do Kwon","year":"2021","journal-title":"Antibodies"},{"key":"10.1016\/j.isci.2026.116632_bib35","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","article-title":"Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity","volume":"165","author":"Huang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116632_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12977-018-0439-9","article-title":"Engineering multi-specific antibodies against HIV-1","volume":"15","author":"Padte","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.isci.2026.116632_bib37","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.molimm.2014.09.017","article-title":"Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A\/L235A and N297A Fc mutations engineered into mouse IgG2a","volume":"63","author":"Arduin","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.isci.2026.116632_bib38","article-title":"Impact of structural modifications of IgG antibodies on effector functions","volume":"14","author":"Damelang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116632_bib39","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2026.116632_bib40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.str.2016.03.005","article-title":"Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region","volume":"24","author":"Tolbert","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.isci.2026.116632_bib41","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116632_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection","volume":"373","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116632_bib43","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.116632_bib44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy","volume":"387","author":"Perelson","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116632_bib45","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1128\/JVI.77.8.5037-5038.2003","article-title":"A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo","volume":"77","author":"Markowitz","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116632_bib46","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1128\/JVI.74.2.627-643.2000","article-title":"A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure","volume":"74","author":"Binley","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116632_bib47","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1128\/jvi.69.9.5723-5733.1995","article-title":"Involvement of the V1\/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding","volume":"69","author":"Wyatt","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116632_bib48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116632_bib49","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1128\/jvi.70.3.1863-1872.1996","article-title":"Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein","volume":"70","author":"Moore","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116632_bib50","doi-asserted-by":"crossref","first-page":"13540","DOI":"10.1073\/pnas.1304985110","article-title":"Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1","volume":"110","author":"Pace","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.116632_bib51","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol. Biol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226020080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226020080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:47:49Z","timestamp":1788223669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226020080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589004226020080"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116632","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral activity of non-neutralizing antibodies during steady-state HIV-1 infection in humanized mice","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116632"}}